Dr. Buza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
T-209
New Haven, CT 06510Phone+1 203-688-2259Fax+1 203-688-5599
Education & Training
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 2006 - 2009
University of Pécs Medical SchoolClass of 1999
Certifications & Licensure
CT State Medical License 2008 - 2025- American Board of Pathology Pathology - Anatomic
Publications & Presentations
PubMed
- 35 citationsSYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan Black, Gary Altwerger
Gynecologic Oncology. 2017-07-01 - 58 citationsIntegrated mutational landscape analysis of uterine leiomyosarcomasJungmin Choi, Aranzazu Manzano, Weilai Dong, Stefania Bellone, Elena Bonazzoli
Proceedings of the National Academy of Sciences of the United States of America. 2021-04-13 - 9 citationsGenital tuberculosis screening at an academic fertility center in the United States.Reshef Tal, Tiwadeye Lawal, Emily Granger, Michael Simoni, Pei Hui
American Journal of Obstetrics and Gynecology. 2020-11-01
Journal Articles
- Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
- Minimal Microsatellite Shift in Microsatellite Instability High Endometrial Cancer: A Significant Pitfall in Diagnostic InterpretationXinyu Wu, Douglas Rottmann, Olivia Snir, Pei Hui, Natalia Buza, Nature
Press Mentions
- Reproducibility of Scoring Criteria for HER2 Immunohistochemistry in Endometrial Serous Carcinoma: A Multi-Institutional Interobserver Agreement StudyFebruary 3rd, 2021
Study Validates Combination Therapy for Aggressive Endometrial CancerJune 26th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
